This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Regeneron Announces First Recipients Of Annual "Regeneron Prize For Creative Innovation"

"We're looking for productive, creative, and innovative young scientists who are not afraid to think outside the box," said Susan Croll, Ph.D., a Regeneron scientist who directs the postdoctoral program at Regeneron.  "The results of their research proposal should have the potential to drive biomedicine forward."

Ten finalists were invited to Regeneron in April to meet with scientists, give presentations about their proposals, and tour the Company's facilities.  The two winning trainees will each receive $50,000, and the institutions nominating the two winners will each receive a $5,000 donation to support their seminar series.  The remaining finalists will each be awarded $5,000, except for the two recipients of "Honorable Mentions," who will each receive $10,000.

"Regeneron is proud to support and encourage early career scientists as they forge their futures in biomedicine.  To build the pipeline of promising new treatments for unmet medical needs, we must also develop the pipeline of talented new medical researchers," concluded Dr. Croll.

About Regeneron Pharmaceuticals Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  The Company was ranked by Science magazine as the top employer in the global biopharmaceutical industry in 2012.  For additional information about the company, please visit www.regeneron.com.

Contact Information:    Peter Dworkin Corporate Communications   914.847.7640   peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs